{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:00:32Z","timestamp":1770894032144,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40268-020-00330-3","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T09:11:03Z","timestamp":1606813863000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dosing Considerations for Antibodies Against COVID-19"],"prefix":"10.1007","volume":"21","author":[{"given":"Million A.","family":"Tegenge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iftekhar","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evi","family":"Struble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basil","family":"Golding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,1]]},"reference":[{"key":"330_CR1","unstructured":"CDC. COVID-19 pandemic planning scenarios. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/planning-scenarios.html. Accessed 25 Aug 2020."},{"key":"330_CR2","unstructured":"Mayo Clinic. Coronavirus disease 2019 (COVID-19). https:\/\/www.mayoclinic.org\/diseases-conditions\/coronavirus\/symptoms-causes\/syc-20479963. Accessed 15 July 2020."},{"issue":"8","key":"330_CR3","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782\u201393.","journal-title":"JAMA"},{"key":"330_CR4","unstructured":"NIH. Potential antiviral drugs under evaluation for the treatment of COVID-19. https:\/\/www.covid19treatmentguidelines.nih.gov\/antiviral-therapy\/. Accessed 25 Aug 2020."},{"key":"330_CR5","unstructured":"US FDA. FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment, another achievement in administration\u2019s fight against pandemic. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment. Accessed 28 Aug 2020."},{"key":"330_CR6","unstructured":"NIH. Immunomodulators under evaluation for the treatment of COVID-19. https:\/\/www.covid19treatmentguidelines.nih.gov\/immune-based-therapy\/immunomodulators\/. Accessed 25 Aug 2020."},{"issue":"5","key":"330_CR7","first-page":"661","volume":"38","author":"E Pujadas","year":"2020","unstructured":"Pujadas E, Chaudhry F, McBride R, Richter F, Zhao S, Wajnberg A, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir Med. 2020;38(5):661-71.e2.","journal-title":"Lancet Respir Med."},{"issue":"12","key":"330_CR8","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMc2001737","volume":"382","author":"L Zou","year":"2020","unstructured":"Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177\u20139.","journal-title":"N Engl J Med."},{"issue":"369","key":"330_CR9","doi-asserted-by":"publisher","first-page":"m1443","DOI":"10.1136\/bmj.m1443","volume":"21","author":"S Zheng","year":"2020","unstructured":"Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ. 2020;21(369):m1443.","journal-title":"BMJ"},{"issue":"10","key":"330_CR10","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1172\/JCI138759","volume":"130","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Investig. 2020;130(10):5235\u201344.","journal-title":"J Clin Investig."},{"issue":"5","key":"330_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ccell.2020.09.007","volume":"38","author":"LF Westblade","year":"2020","unstructured":"Westblade LF, Brar G, Pinheiro LC, Paidoussis D, Rajan M, Martin P, et al. SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. Cancer Cell. 2020;38(5):661-71.e2.","journal-title":"Cancer Cell"},{"issue":"3","key":"330_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/clpt.1994.134","volume":"56","author":"G Levy","year":"1994","unstructured":"Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56(3):248\u201352.","journal-title":"Clin Pharmacol Ther."},{"issue":"9","key":"330_CR13","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1097\/00007890-199605150-00013","volume":"61","author":"RW McGory","year":"1996","unstructured":"McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation. 1996;61(9):1358\u201364.","journal-title":"Transplantation"},{"key":"330_CR14","unstructured":"US FDA. Anthrasil. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/anthrasil. Accessed 21 Aug 2020."},{"issue":"7","key":"330_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40265-016-0577-0","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig SL. Obiltoxaximab: first global approval. Drugs. 2016;76(7):823\u201330.","journal-title":"Drugs."},{"issue":"8","key":"330_CR16","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1080\/19420862.2016.1229722","volume":"8","author":"C Zhou","year":"2016","unstructured":"Zhou C, Lehar S, Gutierrez J, Rosenberger CM, Ljumanovic N, Dinoso J, et al. Pharmacokinetics and pharmacodynamics of DSTA4637A: a novel THIOMAB antibody antibiotic conjugate against Staphylococcus aureus in mice. MAbs. 2016;8(8):1612\u20139.","journal-title":"MAbs."},{"issue":"2","key":"330_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/00006454-199802000-00006","volume":"17","author":"KN Subramanian","year":"1998","unstructured":"Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sanchez PJ, Steichen J, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17(2):110\u20135.","journal-title":"Pediatr Infect Dis J."},{"key":"330_CR18","unstructured":"US FDA. FDA package insert: Synagis (palivizumab). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/103770s5185lbl.pdf. Accessed 21 Aug 2020."},{"key":"330_CR19","unstructured":"medRxiv. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. https:\/\/www.medrxiv.org\/content\/10.1101\/2020.08.12.20169359v1. Accessed 25 Aug 2020."},{"issue":"6506","key":"330_CR20","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.abc7520","volume":"369","author":"TF Rogers","year":"2020","unstructured":"Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956\u201363.","journal-title":"Science"},{"issue":"3","key":"330_CR21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.cell.2020.06.011","volume":"182","author":"AO Hassan","year":"2020","unstructured":"Hassan AO, Case JB, Winkler ES, Thackray LB, Kafai NM, Bailey AL, et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell. 2020;182(3):744-53.e4.","journal-title":"Cell"},{"key":"330_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0065-3527(08)60268-7","volume":"31","author":"JS Porterfield","year":"1986","unstructured":"Porterfield JS. Antibody-dependent enhancement of viral infectivity. Adv Virus Res. 1986;31:335\u201355.","journal-title":"Adv Virus Res."},{"issue":"5596","key":"330_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/265739a0","volume":"265","author":"SB Halstead","year":"1977","unstructured":"Halstead SB, O\u2019Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature. 1977;265(5596):739\u201341.","journal-title":"Nature"},{"issue":"1","key":"330_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1084\/jem.146.1.218","volume":"146","author":"SB Halstead","year":"1977","unstructured":"Halstead SB, O\u2019Rourke EJ, Allison AC. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. J Exp Med. 1977;146(1):218\u201329.","journal-title":"J Exp Med."},{"issue":"4","key":"330_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/infdis\/140.4.527","volume":"140","author":"SB Halstead","year":"1979","unstructured":"Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis. 1979;140(4):527\u201333.","journal-title":"J Infect Dis."},{"issue":"6365","key":"330_CR26","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aan6836","volume":"358","author":"LC Katzelnick","year":"2017","unstructured":"Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929\u201332.","journal-title":"Science"},{"issue":"5","key":"330_CR27","first-page":"e02015","volume":"94","author":"Y Wan","year":"2020","unstructured":"Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol. 2020;94(5):e02015-e2019.","journal-title":"J Virol."},{"issue":"2","key":"330_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","volume":"451","author":"SF Wang","year":"2014","unstructured":"Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014;451(2):208\u201314.","journal-title":"Biochem Biophys Res Commun."},{"issue":"2","key":"330_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0147-9571(81)90003-5","volume":"4","author":"RC Weiss","year":"1981","unstructured":"Weiss RC, Scott FW. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis. 1981;4(2):175\u201389.","journal-title":"Comp Immunol Microbiol Infect Dis."},{"issue":"7","key":"330_CR30","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1128\/AAC.41.7.1571","volume":"41","author":"CV Fletcher","year":"1997","unstructured":"Fletcher CV, Goodroad BK, Cummins LM, Henry K, Balfour HH Jr, Rhame FS. Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS. Antimicrob Agents Chemother. 1997;41(7):1571\u20134.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"330_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/lt.20582","volume":"12","author":"RC Dickson","year":"2006","unstructured":"Dickson RC, Terrault NA, Ishitani M, Reddy KR, Sheiner P, Luketic V, et al. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl. 2006;12(1):124\u201333.","journal-title":"Liver Transpl."},{"issue":"8","key":"330_CR32","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1111\/bcp.13271","volume":"83","author":"S Rozman","year":"2017","unstructured":"Rozman S, Grabnar I, Novakovic S, Mrhar A, Jezersek NB. Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. Br J Clin Pharmacol. 2017;83(8):1782\u201390.","journal-title":"Br J Clin Pharmacol."},{"issue":"6","key":"330_CR33","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/cpt.577","volume":"101","author":"XS Xu","year":"2017","unstructured":"Xu XS, Yan X, Puchalski T, Lonial S, Lokhorst HM, Voorhees PM, et al. Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed\/refractory multiple myeloma. Clin Pharmacol Ther. 2017;101(6):721\u20134.","journal-title":"Clin Pharmacol Ther."},{"issue":"2","key":"330_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/antib9020024","volume":"9","author":"I Mahmood","year":"2020","unstructured":"Mahmood I, Tegenge MA, Golding B. Considerations for optimizing dosing of immunoglobulins based on pharmacokinetic evidence. Antibodies (Basel). 2020;9(2):24.","journal-title":"Antibodies (Basel)."}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00330-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-020-00330-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00330-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T04:49:50Z","timestamp":1615178990000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-020-00330-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["330"],"URL":"https:\/\/doi.org\/10.1007\/s40268-020-00330-3","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"17 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"In-house funding from the U.S. FDA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"No financial conflicts of interest, all the data are in the public domain.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"FDA management consented to this publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All available in references and product Package Inserts.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Non-applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}